After Issues With Adverse Events, the Future of This Experimental Duchenne Muscular Dystrophy Drug Remains Unclear

According to a story from BioSpace, a Phase 1/2 clinical trial testing SGT-001, an investigational treatment for Duchenne muscular dystrophy, has been plagued by problems with side effects and adverse…

Continue Reading After Issues With Adverse Events, the Future of This Experimental Duchenne Muscular Dystrophy Drug Remains Unclear
Sanfilippo Syndrome Type B (MPS IIIB) Clinical Trial Continues to Progress
geralt / Pixabay

Sanfilippo Syndrome Type B (MPS IIIB) Clinical Trial Continues to Progress

According to a story from globenewswire.com, the biopharmaceutical company Abeona Therapeutics, Inc. recently issued an announcement in regards to the company's Phase 1/2 clinical trial, which is testing the company's…

Continue Reading Sanfilippo Syndrome Type B (MPS IIIB) Clinical Trial Continues to Progress
Getting off Immunosuppressants Can Help ANCA Vasculitis Patients Avoid Relapse, Study Suggests
qimono / Pixabay

Getting off Immunosuppressants Can Help ANCA Vasculitis Patients Avoid Relapse, Study Suggests

According to a publication from ANCA Vasculitis News, a new study in International Kidney Reports suggests that stopping treatment of the disease once it goes into remission may lead to…

Continue Reading Getting off Immunosuppressants Can Help ANCA Vasculitis Patients Avoid Relapse, Study Suggests
Experimental Treatment for Multiple Myeloma Earns Orphan Drug Designation
stevepb / Pixabay

Experimental Treatment for Multiple Myeloma Earns Orphan Drug Designation

According to a story from globenewswire.com, the biopharmaceutical company Poseida Therapeutics, Inc. recently announced that the company's investigational product candidate P-BCMA-101 has been granted Orphan Drug Designation from the US…

Continue Reading Experimental Treatment for Multiple Myeloma Earns Orphan Drug Designation
Close Menu